Cognito and Neurotech Reach a Critical Stage with $105 Million

Cognito Therapeutics has raised $105 million in a Series C round to accelerate its pivotal FDA trial, expand collaborations in clinical neurology, and extend its work beyond Alzheimer’s disease into Parkinson’s and other neurodegenerative conditions.

Funding Details

The round was led by Morningside Ventures, IAG Capital Partners, and Starbloom Capital, with participation from New Vintage, Apollo Health Ventures, Benvolio Group, and others. The investment strengthens Cognito’s position as it moves toward regulatory submission and commercial launch of its flagship Spectris™ platform.

Strategic Objectives

CEO Christian Howell outlined three priorities for the new capital:

1. Completion of the HOPE pivotal trial (NCT05637801): Final participants exit in June, with top‑line analysis expected in August.
2. Regulatory readiness: Leveraging FDA Breakthrough designation, Cognito plans to submit a de novo application by year‑end.
3. Health outcomes and cost‑effectiveness research: Through Brain Health Collaboratories, the company will generate data for CMS, commercial payers, and state programs.

Spectris™ Platform

Spectris is an at‑home neurostimulation device designed to evoke synchronized brain activity across networks. Early feasibility studies suggest it may reduce brain atrophy and preserve cognition in patients with mild‑to‑moderate Alzheimer’s disease. The Series C funding will also support expansion into Parkinson’s and other neurodegenerative indications.

Industry Perspective

Gerald Chan, founder of Morningside Ventures, praised Cognito’s convergence of neuroscience, engineering, and patient‑centered design:

“By bringing therapy into the home, easing the load on patients and caregivers, and expanding its impact worldwide, Spectris has the potential to transform treatment for neurodegenerative illnesses.”

Company Background

Founded in 2018, Cognito Therapeutics is a late clinical‑stage neurotechnology company focused on CNS disorders. Its collaborations include the WVU Rockefeller Neuroscience Institute, where it is building value‑based dementia care models. The company expects market launch readiness by 2027, pending regulatory approval.

With $105 million in fresh funding, Cognito is positioned to deliver pivotal trial results, pursue FDA clearance, and expand its neurotech platform into multiple indications. If successful, Spectris could redefine how Alzheimer’s, Parkinson’s, and other neurodegenerative diseases are treated — shifting care into the home and reshaping patient outcomes worldwide.